FDAnews Drug Daily Bulletin
Pharmaceuticals / Research and Development

Circassia’s Cat-SPIRE Sinks in Phase 3 Trial

June 27, 2016
A A

Circassia Pharmaceuticals’ candidate for patients allergic to cats — synthetic peptide immuno-regulatory epitopes — failed in a Phase 3 study, missing its primary endpoint of superiority to placebo in subjects aged 12 to 65 years.

In a clinical trial evaluating 1,245 subjects, the Cat-SPIRE candidate reduced allergy symptoms in almost 60 percent of patients versus placebo at 58.5 percent.

Moving forward, the company will focus on advancing its NIOX asthma management products.

View today's stories